Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCCAP.L Regulatory News (CCAP)

  • There is currently no data for CCAP

Interim Management Statement

11 Jul 2012 07:00

RNS Number : 3769H
Charlemagne Capital Limited
11 July 2012
 



11 July 2012

 

 

Interim Management Statement for the Six Months Ended 30 June 2012

 

 

Charlemagne Capital Limited ("Charlemagne" or the "Group") sets out below the key revenue items and Assets under Management ("AuM") for the first six months of its current financial year.It is expected that the interim financial results will be announced on 18 September 2012.

 

Key highlights and Group AuM

 

§ As at 30 June 2012, Group AuM were US$2.3 billion, down by 2.2% since 1 January 2012;

 

§ Net management fees of US$9.7 million, down 7.6% on the previous six months; and

 

·; The Group remains well-capitalised with a strong and liquid balance sheet.

 

The table below sets out the Group's AuM as at 30 June 2012 and the movements experienced in each product range in the period since 1 January 2012.

 

 

 

01-Jan-12

Net Subscriptions

Net Performance

30-Jun-12

Movement In

AuM (US$m)

(US$m)

(%)

(US$m)

(%)

AuM (US$m)

Period (%)

Magna

260

39

15.0

7

2.5

306

17.7

OCCO

444

50

11.3

18

3.8

512

15.3

Institutional

1,452

(229)

(15.8)

79

5.9

1,302

(10.3)

Specialist

172

(10)

(5.8)

(5)

(3.0)

157

(8.7)

Total

2,328

(150)

(6.4)

99

4.4

2,277

(2.2)

 

Notes:

Closing AuM is stated as including all subscription and redemption orders received for the relevant funds as at the close of the period but not processed until the first dealing date of the following period.

 

Unaudited revenue numbers for the six months ended 30 June 2012

 

Net management fees receivable were US$9.7 million compared with US$10.5 million for the previous six months and US$12.1 million for the comparable period of 2011, reflecting the lower average AuM offset in part by an increase in net margin in the first half of 2012.

 

Crystallised performance fees were US$0.9 million compared with US$0.1 million for the comparative period in 2011.

 

Accruing performance fees1 for 2012 which have not crystallised were US$3.5 million compared with US$1.5 million as at the same date in 2011.

 

 

 

 

____________________________________________________________________________

1Performance fees accrue throughout the reporting period in the accounts of each relevant fund. It is the group's accounting policy only to recognise such revenues as they crystallise at the year-end date of the fund or, in certain cases, on redemption. Levels of accrued performance fees at any particular time should not be seen as necessarily indicative of the eventual crystallised figures, especially in periods of above average market volatility.

 

Summary

 

After a strong opening two months of the year, emerging markets softened over the remainder of the first half, as macroeconomic data from most major economies of the world came below expectations. This in turn increases the likelihood that earnings forecasts, both in developed and emerging economies will be revised downwards, although valuations in the emerging markets already appear to have discounted this outcome. Oil importing Turkey, whose market rose 28% over the six months in US$, was one of the best performers, while amongst the larger markets Brazil lagged, with a decline of 8%.

 

Over the period, the relative performance of Charlemagne's equity strategies was strong, with six of the eight Magna sub-funds in the top half of their FactSet Morningstar peer group comparisons and none in the bottom quartile.

 

There have been positive net inflows into the Magna funds over the first half of the year particularly into the Latin American and GEMs Dividend strategies. Institutional mandates experienced outflows mainly in the first quarter which was partially offset in the second quarter with the acquisition of a new US$130 million institutional Latin American mandate. The OCCO Eastern European Fund reopened during the period and the US$120 million new capacity has been fully allocated with US$70 million still to be invested in the third quarter. The fund has therefore been closed once again to new investors.

 

The trading environment remains challenging, with markets volatile, investor confidence fragile and fund flows subdued. The Group has negotiated these conditions well; achieving the key objective of making money for our investors, but overall reduced asset values has had a direct impact on group revenues. We have continued to improve operational efficiency and to take action on costs, where such measures are not to the detriment of delivering investment performance for clients, but market values will need to rise in order for the group to see meaningful levels of profitability from recurring fee sources.

 

 

 

Enquiries:

 

Charlemagne Capital

 

Jayne Sutcliffe, Chief Executive

Tel. 020 7518 2100

Lloyd Jones, Finance Director

Tel. 01624 640200

 

 

Singer Capital Markets Ltd

+44 203 205 7500

Jonny Franklin-Adams

 

 

 

Smithfield Consultants

Tel. 020 7360 4900

John Kiely

Ged Brumby

 

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSKMGMNNGZGZZM
Date   Source Headline
16th Sep 20217:00 amRNSInterim Results
11th Aug 202112:33 pmRNSResult of AGM
4th Aug 20217:00 amRNSProposed reverse takeover of Smarttech247
16th Jul 20211:00 pmRNSRevised Notice of AGM & Adjournment of AGM
30th Jun 20215:51 pmRNSFinal Results for the year ended 31 December 2020
6th Apr 20217:30 amRNSSuspension - Conduity Capital PLC
1st Apr 20213:45 pmRNSDirector/PDMR Shareholding
31st Mar 20214:28 pmRNSTR-1: Notification of major holdings
30th Mar 202111:38 amRNSTR-1: Notification of major holdings
29th Mar 20214:41 pmRNSSecond Price Monitoring Extn
29th Mar 20214:35 pmRNSPrice Monitoring Extension
29th Mar 20212:05 pmRNSTR-1: Notification of major holdings
29th Mar 20211:48 pmRNSDirector/PDMR Shareholding
25th Mar 20212:00 pmRNSTR-1: Notification of major holdings
25th Mar 202112:47 pmRNSTR-1: Notification of major holdings
24th Mar 20214:41 pmRNSSecond Price Monitoring Extn
24th Mar 20214:36 pmRNSPrice Monitoring Extension
24th Mar 202111:05 amRNSSecond Price Monitoring Extn
24th Mar 202111:00 amRNSPrice Monitoring Extension
24th Mar 20219:25 amRNSIssue of Equity and Total Voting Rights
24th Mar 20219:05 amRNSSecond Price Monitoring Extn
24th Mar 20219:00 amRNSPrice Monitoring Extension
24th Mar 20217:00 amRNSAIM Rule 15 and Corporate Update
19th Mar 20214:41 pmRNSSecond Price Monitoring Extn
19th Mar 20214:36 pmRNSPrice Monitoring Extension
19th Mar 202111:00 amRNSPrice Monitoring Extension
19th Mar 20219:00 amRNSPrice Monitoring Extension
19th Mar 20218:42 amRNSTR-1: Notification of major holdings
16th Mar 202110:19 amRNSTR-1: Notification of major holdings
15th Mar 20214:41 pmRNSSecond Price Monitoring Extn
15th Mar 20214:35 pmRNSPrice Monitoring Extension
5th Mar 20214:40 pmRNSSecond Price Monitoring Extn
5th Mar 20214:35 pmRNSPrice Monitoring Extension
1st Mar 20218:47 amRNSTR-1: Notification of major holdings
26th Feb 202112:02 pmRNSIssue of Equity and Total Voting Rights
26th Feb 20219:42 amRNSTR-1: Notification of major holdings
22nd Feb 202112:07 pmRNSIssue of Equity and Total Voting Rights
16th Feb 202110:50 amRNSTR-1: Notification of major holdings
8th Feb 20218:38 amRNSIssue of Equity and Total Voting Rights
3rd Feb 202112:51 pmRNSIssue of Equity and Total Voting Rights
3rd Feb 20217:42 amRNSTR-1: Notification of major holdings
1st Feb 202111:04 amRNSIssue of Equity and Total Voting Rights
28th Jan 20214:41 pmRNSSecond Price Monitoring Extn
28th Jan 20214:35 pmRNSPrice Monitoring Extension
28th Jan 20212:06 pmRNSSecond Price Monitoring Extn
28th Jan 20212:00 pmRNSPrice Monitoring Extension
27th Jan 20219:53 amRNSIssue of Equity and Total Voting Rights
26th Jan 20211:53 pmRNSTR-1: Notification of major holdings
25th Jan 20217:50 amRNSTR-1: Notification of major holdings
20th Jan 20213:30 pmRNSIssue of Equity and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.